


DFS in patients initiating neratinib treatment less than 1 year after completing adjuvant trastuzumab

Intention-to-treat population




No. at risk

Neratinib	1152	1047	1023	1002	971	936	899	833	526
Placebo	1145	1100	1063	1035	997	964	929	865	554

* p-value descriptive



Interim 5-year DFS in patients initiating neratinib treatment less than 1 year after completing adjuvant trastuzumab




No. at risk

Neratinib	1152	1054	1017	976	855	728	717	684	615	465	301
Placebo	1145	1080	1034	982	894	770	753	724	644	504	321

* p-value descriptive



DFS in HR+ patients initiating neratinib treatment less than 1 year after completing adjuvant trastuzumab




No. at risk

Neratinib	670	605	593	577	559	538	516	485	307
Placebo	664	638	619	602	580	563	541	501	326

* p-value descriptive



Interim 5-year DFS in HR+ patients initiating neratinib treatment less than 1 year after completing adjuvant trastuzumab




No. at risk

Neratinib	670	614	589	567	501	436	432	416	375	283	181
Placebo	664	630	604	575	520	447	434	417	370	284	171

* p-value descriptive



DFS in HR- patients initiating neratinib treatment less than 1 year after completing adjuvant trastuzumab




No. at risk

Neratinib	482	442	430	425	412	398	383	348	219
Placebo	481	462	444	433	417	401	388	364	228

* p-value descriptive



Interim 5-year DFS in HR- patients initiating neratinib treatment less than 1 year after completing adjuvant trastuzumab




No. at risk

Neratinib	482	440	428	409	354	292	285	268	240	182	120
Placebo	481	450	430	407	374	323	319	307	274	220	150

* p-value descriptive

DFS in centrally confirmed HER2+ (ccHER2+) patients initiating neratinib treatment less than 1 year after completing adjuvant trastuzumab




No. at risk

Neratinib	743	697	685	675	658	635	609	557	352
Placebo	703	684	658	638	617	596	574	536	336

* p-value descriptive



Interim 5-year DFS in ccHER2+ patients initiating neratinib treatment less than 1 year after completing adjuvant trastuzumab



No. at risk

Neratinib	743	698	683	660	583	493	484	459	410	312	195
Placebo	703	667	638	606	554	481	472	451	397	315	196

* p-value descriptive

